QT Imaging is proud to announce the Opening Bell Ceremony at the Nasdaq MarketSite in Times Square.
The study was published in Academic Radiology, online, in January 2024: A Multireader Multicase (MRMC) Receiver Operating Characteristic (ROC) Study Evaluating Noninferiority of Quantitative Transmission (QT) Ultrasound to Digital Breast Tomosynthesis (DBT) on Detection and Recall of Breast Lesions – Academic Radiology
The Center for New Medicine is one of the largest integrative medical clinics in North America, providing a personalized approach to health care including cancer prevention, its early detection, and internal medicine. With the incorporation of the QT Imaging Breast Acoustic CT™ Scanner, the Center for New Medicine will expand their innovative services in women’s and breast health.
QT Imaging Holdings, Inc. a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced that the Board of Directors has appointed former GigCapital5, Inc. CEO Dr. Raluca Dinu as Active Chief Executive Officer and member of the Board of Directors, effective March 12, 2024.
QT Imaging is pleased to announce the delivery of a Breast Acoustic CT™ Scanner under a unique collaboration with the Department of Radiation Oncology, and Radiation Treatment Program at the Sunnybrook Health Sciences Centre in Toronto, Canada, one of the largest cancer centers in Canada, and The University of Illinois, Urbana-Champaign, Department of Electrical and Computer Engineering and Grainger College of Engineering. This collaboration is part of a five-year research grant from National Institutes of Health/National Cancer Institute to develop an inexpensive, portable, safe, and repeatable imaging approach capable of accurate and early identification of response of breast cancer patients to neoadjuvant chemotherapy (NAC).
QT Imaging announces the first commercial sale of a QTI Breast Acoustic CT™ System to True Health Center for Functional Medicine. QTI’s inaugural customer was born as a result of the collaboration with our previously announced strategic distribution partner and represents the business model to be deployed by the company.
QT Imaging Holdings Expected to Begin Trading on NASDAQ Under Ticker Symbol “QTI” on March 5, 2024
QT Imaging CEO to present at leading conference on cancer treatment, testing, and monitoring modalities
QT Imaging and GigCapital5 to Merge
GigCapital5 and QT Imaging have entered into a definitive business combination agreement that would result in QT Imaging becoming a publicly listed company
The QTscan to be used to improve the assessment of tumor response in neo-adjuvant chemotherapy treatments
QT Imaging expected to be public in the first half of 2023
QTscan delivers safe, accurate monitoring of breast cancer treatment.
Study provides a more accurate description of tissue changes during the menstrual cycle – the first time such observations have been made in vivo.
QT Imaging’s low frequency transmitted ultrasound volography™ had sensitivity of 85.7% sensititivity compared to mpMRI at 65.3% in a blinded sector-based analysis.
QT Imaging meets non-inferiority endpoint for mass detection when compared to conventional full field digital mammography (FFDM)
US Capital Global Securities engaged as lead placement agent by innovative MedTech company developing new-paradigm ultrasound technology for breast cancer screening.
QT Imaging signs distribution agreement with Freedom Ventures for its FDA-cleared breast scanner
First-in-class, first-in-human study compares new breast imaging modality to digital mammography
Common mission of safe, advanced, affordable medical imaging brings together international leaders
CEO, John Klock, MD, and Principal Scientist, James Wiskin, Ph.D, Present Innovation in Quantitative Transmission Ultrasound
James Wiskin, Ph.D, QT Ultrasound’s Principal Scientist, invited to lecture on innovative technology
3D Transmission Ultrasound Technology Advances How We Look at Breast Health
QT Ultrasound’s principal scientists and technologists deliver five presentations at key industry event
Chief Medical Officer, Rajni Natesan, MD, MBA and Principal Scientist, Bilal Malik, Ph.D, will introduce cutting edge research at RSNA 2018
The FDA has designated the QT Ultrasound Breast Scanner as meeting an unmet medical need for screening women at high risk for breast cancer
As part of the QT Ultrasound Breast Scanner the new viewer for true 3D breast images offers radiologists clarity, customizable views, faster response time, and powerful research mode.
Transmission ultrasound technology provides 360-degree images and a new level of clarity for breast scans, without breast compression.